Impact of age and comorbidities on the efficacy of FC and FCR regimens in chronic lymphocytic leukemia

被引：9

作者：

Strugov, Vladimir ^{[1
]}

Stadnik, Elena ^{[1
,2
]}

Virts, Yulia ^{[1
]}

Andreeva, Tatyana ^{[1
]}

Zaritskey, Andrey ^{[1
,2
]}

机构：

[1] Almazov Natl Med Res Ctr, Inst Hematol, Akkuratova St 2, St Petersburg 197341, Russia

[2] Pavlov First St Petersburg State Med Univ, Div Hematol, St Petersburg 197022, Russia

来源：

ANNALS OF HEMATOLOGY | 2018年 / 97卷 / 11期

关键词：

CLL; Chronic lymphocytic leukemia; CIRS-G; Comorbidities; FCR; MYELOID-LEUKEMIA; SURVIVAL; TRIAL; CELL; FLUDARABINE; CHEMOIMMUNOTHERAPY; CYCLOPHOSPHAMIDE; PROGRESSION; EXPRESSION; GUIDELINES;

D O I：

10.1007/s00277-018-3409-3

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

CLL is an aging-associated neoplasm with median age at diagnosis >65years. Little is known about safety and efficacy of FC/FCR regimens in elderly CLL patients with multiple comorbidities. We retrospectively revised medical records of 90 patients treated with FC/FCR regimens in our clinic. Data on demographic and biological characteristics, comorbidities, response to therapy, and treatment-associated adverse events were analyzed. Compared to FC, FCR yielded higher rates of OR (93.6 vs. 81.4%, p=.109) and CR (72.3 vs. 46.5%, p=.018). This translated in longer EFS (median 52 vs. 19months, p=<.001) and OS (median 89 vs. 45months, p=.001). Elderly patients (65 years) had more comorbidities and higher median CIRS-G score (7 vs. 4, p<.001). However, no association was found between CIRS-G score and survival. Decreased renal function was associated with dismal prognosis in patients treated with FCR.

引用

页码：2153 / 2161

页数：9

共 35 条

[1]

[Anonymous], 2015, CANC FACTS FIG 2015

[2] Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet [J].

Baccarani, Michele ;

Cortes, Jorge ;

Pane, Fabrizio ;

Niederwieser, Dietger ;

Saglio, Giuseppe ;

Apperley, Jane ;

Cervantes, Francisco ;

Deininger, Michael ;

Gratwohl, Alois ;

Guilhot, Francois ;

Hochhaus, Andreas ;

Horowitz, Mary ;

Hughes, Timothy ;

Kantarjian, Hagop ;

Larson, Richard ;

Radich, Jerald ;

Simonsson, Bengt ;

Silver, Richard T. ;

Goldman, John ;

Hehlmann, Rudiger .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (35) :6041-6051

[3]

BINET JL, 1981, CANCER-AM CANCER SOC, V48, P198, DOI 10.1002/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO

[4]

2-V

[5] Computed tomography scans do not improve the predictive power of 1996 national cancer institute-sponsored working group chronic lymphocytic leukemia response criteria [J].

Blum, Kristie A. ;

Young, Donn ;

Broering, Sarah ;

Lucas, Margaret S. ;

Fischer, Beth ;

Lin, Thomas S. ;

Grever, Michael R. ;

Byrd, John C. .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (35) :5624-5629

[6] Minimal Residual Disease Quantification Is an Independent Predictor of Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia: A Multivariate Analysis From the Randomized GCLLSG CLL8 Trial [J].

Boettcher, Sebastian ;

Ritgen, Matthias ;

Fischer, Kirsten ;

Stilgenbauer, Stephan ;

Busch, Raymonde M. ;

Fingerle-Rowson, Guenter ;

Fink, Anna Maria ;

Buehler, Andreas ;

Zenz, Thorsten ;

Wenger, Michael Karl ;

Mendila, Myriam ;

Wendtner, Clemens-Martin ;

Eichhorst, Barbara F. ;

Doehner, Hartmut ;

Hallek, Michael J. ;

Kneba, Michael .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (09) :980-988

[7] Trends in long-term survival of patients with chronic lymphocytic leukemia from the 1980s to the early 21st century [J].

Brenner, Hermann ;

Gondos, Adam ;

Pulte, Dianne .

BLOOD, 2008, 111 (10) :4916-4921

[8] USE OF FAMILY SPECIFIC LEADER REGION PRIMERS FOR PCR AMPLIFICATION OF THE HUMAN HEAVY-CHAIN VARIABLE REGION GENE REPERTOIRE [J].

CAMPBELL, MJ ;

ZELENETZ, AD ;

LEVY, S ;

LEVY, R .

MOLECULAR IMMUNOLOGY, 1992, 29 (02) :193-203

[9] National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment [J].

Cheson, BD ;

Bennett, JM ;

Grever, M ;

Kay, N ;

Keating, MJ ;

OBrien, S ;

Rai, KR .

BLOOD, 1996, 87 (12) :4990-4997

[10] Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia [J].

Damle, RN ;

Wasil, T ;

Fais, F ;

Ghiotto, F ;

Valetto, A ;

Allen, SL ;

Buchbinder, A ;

Budman, D ;

Dittmar, K ;

Kolitz, J ;

Lichtman, SM ;

Schulman, P ;

Vinciguerra, VP ;

Rai, KR ;

Ferrarini, M ;

Chiorazzi, N .

BLOOD, 1999, 94 (06) :1840-1847

← 1 2 3 4 →